Expert panelists discuss priming with bispecifics in patients with multiple myeloma, using patient cases to illustrate how CRS and ICANS are diagnosed and managed.
EP. 2: Role of Multidisciplinary Care in With MM Receiving Bispecific AntibodiesMay 3rd 2023
Shared insight on the respective roles of a multidisciplinary care team involved in the management of multiple myeloma and associated adverse events.
EP. 3: Patient Case 1: Development of CRS on a BCMA-Targeted Bispecific AntibodyMay 10th 2023
Expert panelists review the first patient case of multiple myeloma wherein cytokine release syndrome (CRS) develops during treatment with a BCMA-targeted bispecific antibody.
EP. 4: Administering Step-up and Treatment Doses of Bispecifics in MMMay 10th 2023
A brief review of bispecific antibody dosing strategies in multiple myeloma to improve patient outcomes and address concurrent adverse events.
EP. 5: Cytokine Release Syndrome Grading and Management Strategies in MMMay 17th 2023
Comprehensive insight on the grading system for cytokine release syndrome and available treatment strategies utilized in practice when patients with multiple myeloma develop CRS.
EP. 6: Patient Case 2: Development of ICANS on a BCMA-Targeted Bispecific AntibodyMay 17th 2023
Switching focus to the second patient case of multiple myeloma, panelists reflect on the prevalence and impact of ICANS on patients being treated with bispecific antibodies.
EP. 7: Management of ICANS Associated with Bispecific Antibodies in MMMay 24th 2023
A brief review of available management strategies used in practice when patients with multiple myeloma develop immune effector cell-associated neurotoxicity syndrome.
EP. 8: Patient Case 3: Development of CRS on a Non-BCMA Targeted Bispecific AntibodyMay 24th 2023
Centering discussion on the third patient case of multiple myeloma, key opinion leaders consider the development of CRS on non-BCMA targeted bispecific antibody therapy.
EP. 9: Clinical Pearls on CRS and ICANS Management in Multiple MyelomaMay 31st 2023
Moderator Ajai Chari, MD, leads the panel in sharing clinical pearls for management of CRS and ICANS in multiple myeloma before closing out the final module.